The prevalence of obesity and its relationship to cardiometabolic risk factors in the LIPIDOGRAM studies
An increase in body mass index and visceral obesity was observed among Polish primary health care patients included in the LIPIDOGRAM study from 2004 to 2015. As patients age, the number of cases of diabetes and dyslipidemia increases. These changes cause an increase in cardiometabolic risk.
Authors
- Tadeusz Osadnik (ORCID: https://orcid.org/0000-0002-3202-6972)
- Martyna Fronczek (ORCID: https://orcid.org/0000-0003-3669-1416)
- Dariusz Nowak (ORCID: https://orcid.org/0000-0003-3445-6930)
- Agnieszka Kuras (ORCID: https://orcid.org/0000-0002-0541-5614)
- Peter E. Penson (ORCID: https://orcid.org/0000-0001-6763-1489)
- Marek Gierlotka (ORCID: https://orcid.org/0000-0001-5639-2128)
- P. Toth
- Jacek J Jóźwiak
- G Y H Lip
- Tomasz Czapor
- Marcin Miga
- Dimitri P Mikhailidis
- Agata Kulkowska-Gaj
- Maciej Banach
- Tomasz Tomasik
- Adam Windak
Institutions
- John Paul II Catholic University of Lublin (PL)
- Opole University of Technology (PL)
- Jagiellonian University (PL)
- Częstochowa University of Technology (PL)
- Johns Hopkins University (US)
- University of Liverpool (GB)
- Medical University of Silesia (PL)
- University of Opole (PL)
- Johns Hopkins Medicine (US)
- The Royal Free Hospital (GB)
- Liverpool Heart and Chest Hospital (GB)
- CGH Medical Center (US)
- Medical University of Lodz (PL)
- University College London (GB)
- Liverpool John Moores University (GB)
- Aalborg University (DK)
Publication Details
- Journal
- Kardiologia Polska
- Published
- 2026-01-26
- DOI
- https://doi.org/10.33963/v.phj.110885
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Valeant Pharmaceuticals International
- Mylan
- Śląski Uniwersytet Medyczny w Katowicach
- Servier
- Uniwersytet Śląski w Katowicach
- Esperion Therapeutics
- Daiichi Sankyo Europe